In this paper, we describe the accomplishments of the initial phase of the Human Genome Project, with particular attention to the progress made toward achieving the defined goals for constructing genetic and physical maps of the human genome and determining the sequence of human DNA, identifying the complete set of human genes, and analyzing the need for adequate policies for using the information about human genetics in ways that maximize the benefits for individuals and society.
The purpose of the Human Genome Project (HGP) is to generate a set of information, material, and technology resources that will be readily available to the entire scientific community. This "scientific infrastructure" will vastly improve the ability of investigators from a variety of fields to apply molecular approaches to the study of a wide range of biological problems as we enter the 21st century. Specifically, the HGP is intended to develop, efficiently and cost-effectively, detailed genetic and physical maps of the human genome, determine the complete nucleotide sequence of human DNA, and develop the new technology necessary to achieve these ambitious goals. This information will lead, in turn, to the locations of the estimated 50,000-100,000 genes within the human genome. The goals of the HGP also include the construction of detailed genetic and physical maps and acquisition of DNA sequence information characterizing the genomes of several nonhuman organisms used extensively in research laboratories as model systems. This review focuses on progress on the characterization of the genome of Homo sapiens; progress on the characterization of the genomes of several model organisms is discussed in the accompanying set of papers.
Among the many issues raised in the early discussions of the genome project in the late 1980s was its feasibility. There was considerable skepticism that technology adequate to the challenge of building dense maps and sequencing billions of base pairs of DNA was available or could be developed in a reasonable period of time. Thus, perhaps the most important lesson that has been learned from the HGP is that it can be done.
Indeed, from the beginning, progress in genomics research has been remarkably rapid (Fig. 1 ). In part, this has been due to the strategic planning that has been an integral part of the HGP. In 1990, the U.S. agencies involved [the National Institutes of Health (NIH) National Center for Human Genome Research (NCHGR) and the Department of Energy (DOE) Office of Health and Environmental Research] publicly presented a plan that described the scientific and other goals for the first phase of the project (2) . Even in 1990, the gathering pace of genome research was beginning to be evident, and the NIH/DOE plan noted that the general plan that had been described just two years earlier by the National Research Council (3) was "still appropriate, but some of the details must be changed as improvements in the technology have occurred in the past two years." As for the 1990 plan, it was refined and extended just three years later (4) "because a much more sophisticated and detailed understanding of what needs to be done and how to do it is now available." And in 1995, the signs are rapidly emerging that the 1993 plan is similarly being superseded by scientific developments, so that a new plan will likely be needed by 1997.
Genetic Mapping
In late 1994, the human genetic linkage map became the first of the major goals of the HGP to be reached, when an international group of investigators, representing contributions from >100 laboratories, published a comprehensive human linkage map (5) . The map contains 5826 loci covering 4000 centimorgans (cM) on a sex-averaged map, representing an average marker density of 0.7 cM. This is well beyond the initial HGP goal of a 2-to 5-cM map. The rapid success in genetic linkage mapping was the result, in large part, of the introduction of microsatellite-based genetic markers (6, 7) and the development of large-scale, semiautomated methods for marker isolation, typing, and analysis (8, 9 ).
This map is much more detailed than any previous human linkage map; yet, it is still far from ideal. Only 908 of the markers on it are ordered with high confidence (odds of >1000:1) (5). These constitute a "framework map" of about 4-cM resolution. The additional 4500 markers are 10841 localized with respect to the markers of the framework map with odds for order between 10:1 and 1000:1. There also are certain technical problems with microsatellites that make them more difficult to use than one would like, especially for highly automated approaches to genotyping (10) . Continued improvement in the technology for genetic mapping and genotyping, giving more reliable order information, improved markers, and better methods for genotyping on a large scale would make the human genetic linkage map even more useful.
Physical Mapping
Considerable progress has also been made in constructing physical maps of the human genome. The current 5-year HGP goal for physical mapping calls for completion of maps based on sequence-tagged site (STS)* markers, with an average spacing of 100 kb. STS-based physical maps were taken as the HGP goal because STSs provide a "common mapping language"; since they can be used as markers in a variety of mapping techniques, STSs can be used to integrate and compare physical maps constructed by different techniques (11) . For the same reason, STSs can also be used to integrate genetic and physical maps. STSs have rapidly gained acceptance as the markers of choice for map construction ( Fig. 1B ; most of the PCR probes in the GDB are STSs), and the goal of a physical map of the human genome with a resolution of 100 kb-i.e., 30,000 STSs-is well within sight. Already, more than 23,000 STSs (mapped at least to a chromosome) have been deposited in GDBt (as of June 1, 1995) .
By using a variety of mapping strategies, long-range clone contiguity has been achieved for several individual chromo- (1) ; for these years, the number of polymorphisms was approximated by the number of polymorphic D-segments, while the number of mapped genes was approximated by the number of genes. In the case of DNA sequences (C), the number shown is the amount of sequence in GenBank and is based on the earliest date of a published reference for each entry.
somes. Clone/STS maps of the entire euchromatic regions of chromosomes 21 (12) and Y (13) (14) .
As an alternative to the chromosomespecific approaches that have led to these individual maps, a few groups have pursued genome-wide assembly strategies for constructing physical maps. In 1994, French scientists published a low-resolution physical map of the entire human genome (15) New sequencing strategies have also been developed. The most commonly employed strategy for large-scale sequencing remains the "shotgun" approach, in which each member of a set of randomly-generated subclones of the target region is completely sequenced and the sequence of the target region is reconstructed by a computer-based assembly process that compares the sequences of the subclones and finds the overlapping regions. However, for statistical reasons, a pure shotgun approach requires a very large amount of random sequencing (to at least a 10-fold redundancy) to obtain the complete target sequence and is, therefore, quite expensive. To reduce this cost, most sequencing efforts have employed modifications of the basic shotgun approach, involving random sequencing to a lower redundancy, partial sequence assembly, and completion by a more directed strategy. Other approaches to reducing redundancy (24, 25) promise to lead to further increases in overall efficiency.
Alternatives involving completely directed strategies for large-scale sequencing have also been developed. Transposon-based sequencing strategies (refs. 26 and 27; P. Cartwright, R. Gesteland, and R. Weiss, personal communication) which involve using mapped transposon insertions within the region to be sequenced as sites for initiating sequencing reactions promise to reduce both the amount of sequence redundancy needed to achieve closure and the difficulty of sequence assembly. New approaches to primer walking, involving the use of short oligonucleotides to construct sequencing primers in situ (28, 29) or inexpensive oligonucleotide synthesis (T. Brennan The term "expressed sequence tag" (EST) has been used to refer to a short DNA sequence derived from a cDNA clone and used to identify a genomic coding sequence (47) . A considerable number of ESTs have been collected in a public repository, dbEST (188,122 as of June 15, 1995; ref. 48) , and a much larger number will become publicly available by the end of 1995 through an effort supported by the pharmaceutical company Merck; over 100,000 ESTs from this effort have been put into dbEST in the first few months of operation. STSs derived from these ESTs will rapidly be incorporated into physical maps through the efforts of an international mapping consortium (49) . These projects lend confidence that the slope of the curve in Fig. 1D will soon increase significantly and that half or more of the genes in the human genome will be localized on physical maps within the next few years. However, the actual number of genes that can be identified and mapped by this approach cannot be predicted, nor can the proportion of the total number of human genes they will represent. The number of genes that can be identified in this way depends entirely on the quality of the cDNA libraries from which the ESTs are obtained, and cDNA libraries that represent the complete set of human genes have not been constructed.
Medical Applications
The term "gene identification" is also used more broadly to describe the isolation of the gene(s) underlying a particular phenotype or trait, such as a disease. In this sense, gene identification is a biological problem with considerable medical significance that HGP resources are already helping to solve. It is one measure of the success of the HGP to date that, through the use of these new tools, the speed with which disease genes are being found is rapidly increasing. New disease genes are being found and reported at a rate of several per month, compared with a few per year not so long ago (50) .
During the past 2 years, many genes for human diseases have been isolated by using the powerful methods of positional cloning (51) , where no prior knowledge of the gene's function is available. In contrast to positional cloning, functional cloning or candidate-gene strategies make use of information that is known about the gene product and/or the function of the gene of interest that suggest it as a particularly good candidate for the affected gene in a particular disease. For example, keratins are the major class of proteins found in skin cells. The effects of mutations on the properties of certain keratin proteins and the observation that mice in which such mutant genes are expressed exhibit features of epidermolysis bullosa simplex (EBS) led to the discovery that mutations in the human K5 and K14 keratin genes are responsible for the severest forms of EBS in humans (52) .
The candidate-gene methods have also taken advantage of the improvement in genomic maps, resources, and technologies, and, as genomic maps improve and become more populated with gene sequences, a new strategy is emerging. Known as "positional candidate" cloning (50, 53) , this approach begins with mapping the disease gene to a small chromosomal interval. All genes located in that interval can then be tested for their involvement, starting with any whose product functions in a way that suggests possible involvement. In other words, a gene becomes a candidate not only by virtue of the properties of its protein product but by its map location as well.
As more human genes have been identified and cloned, new insights are already being gained into human biology and disease. Some of these might not be surprising in that they show that many aspects of human molecular genetics are familiar and similar to those seen in more wellstudied organisms. For instance, as elaborated below, different phenotypes have now been found to arise from different mutations in a single human gene, and similar phenotypes have been found to arise from mutations in different (related) genes. Yet, this similarity is itself important because it confirms once more that many of the lessons we have learned about the biology of nonhuman organisms will be directly applicable to our understanding of human biology.
Several human genes have been analyzed sufficiently thoroughly that analysis of mutational spectra has been possible. Mutations in the receptor tyrosine kinase gene RET can give rise to any of four different syndromes: familial medullary thyroid carcinoma (54), multiple endocrine neoplasia types 2A (54, 55) and 2B (56) , and Hirschsprung disease (57, 58) .
There is no reported cancer association with the latter condition. Similarly, while a large number of mutations in the CFTR gene cause cystic fibrosis (CF) (of varying degrees of severity) (59), mutations in CFTR have also been found in patients who do not exhibit the standard pulmonary symptoms of CF. A significant fraction of otherwise healthy males who are infertile due to a congenital bilateral absence of the vas deferens (CBAVD) carry one or two known CFTR mutations (60) , although recent evidence indicates that the CBAVD condition itself is genetically heterogeneous (61) . Genetic (70, 71) .
Kallmann syndrome is a condition characterized by an unusual constellation of seemingly unrelated features: hypogonadism resulting from an endocrinological problem (deficiency of hypothalamic gonadotropin-releasing hormone) and anosmia (inability to smell). Isolation of the KAL gene (72, 73) led to the recognition that the predicted KAL gene product was related to neural-adhesion molecules. This is consistent with a role of the gene product in embryonic neural migration and with the observation of a common developmental pathway of two types of neurons that originate in the olfactory placode: the olfactory neurons and the neurons that produce gonadotropin-releasing hormone.
Analysis of other genetic diseases in humans has led to the identification of a previously unobserved mutational mechanism. Fragile X syndrome (74), spinal and bulbar muscular atropy (75) , myotonic dystrophy (76) (77) (78) , Huntington disease (79) , and several others have been found to be caused by trinucleotideexpansion mutations in which the number of copies of a trinucleotide repeat sequence is significantly increased in affected compared with nonaffected individuals.
Charcot-Marie-Tooth disease type 1A (CMT1A) represents another unique (to date) genetic situation, in that it most frequently results from duplication of the region of chromosome 17 containing the PMP22 gene (80) . Hypotheses suggesting that this is a gene dosage effect are being tested. Point mutations in PMP22 have also been found in patients with CMT1A (80) and, as in the case of RET and CFTR, other mutations in PMP22 have been found to be responsible for other clinical conditions: Dejerine-Sottas syndrome (81) and, possibly, hereditary neuropathy with liability to pressure palsies (82) .
Informatics
With respect to genomics, informatics issues range from the algorithmic and datamanagement needs of mapping and sequencing projects to the dissemination of data to the scientific community, and the development of adequate informatics approaches to this variety of issues has been an important area of research since the inception of the HGP. Data analysis and data management are actually open-ended problems in that today's solutions will, in general, have a limited lifetime as new approaches to genomic analysis and more data are developed. Nonetheless, much progress has been made in genome informatics in the past 5 years. A considerable number of individual laboratories have developed and are using computer-based systems for automating the acquisition, management, analysis, and distribution of experimental data. Similarly, a number of new data bases have been created for the purpose of allowing the rapid distribution of the findings of genome research.
In fact, the number of data sources and programs of interest is too large to summarize in this article, but information about many may be obtained electronically from http://www.nchgr.nih.gov. The current state of genome informatics is driven by the rapidly expanding capabilities afforded by the increased capacity of computers and networks. Through the use of ftp sites and the World Wide Web, for example, many genome centers provide electronic access to much larger amounts of data and less refined data than could be published. While this system has the advantage of allowing those who generate genome data to take the responsibility for its rapid provision to the research community, it can sometimes appear to be overly anarchic. More seriously, it can pose some serious challenges to the users of the data as they attempt to locate diverse information sources and integrate data in diverse formats. Recently, both the central data bases and independent software developers have made significant progress on data-access systems and tools.
Ethical, Legal, and Social Implications (ELSI) It was recognized almost from the outset of the HGP that the increased knowledge of human biology and human disease that would come from application of genomic information would raise a number of substantive ethical and policy issues for individuals and for society. Accordingly, an ELSI research program has been an integral element of genome programs around the world. In the U.S., the ELSI research program has focused on identifying and addressing a few high priority areas raised by the most immediate potential applications or consequences of genome research. These are ethical issues surrounding genetics research, responsible clinical integration of new genetic technologies, privacy and fair use of genetic information, and professional and public education about these issues.
Research and education projects have been funded in each of these priority areas. In pursuing these goals, there has been an emphasis on the integration of sound scientific knowledge with an understanding of the many historical, ethnocultural, social, and psychological factors that influence policy development and service delivery in human genetics. The first of these projects are now beginning to be completed, and the research results are leading to the identification of policy options intended to ensure that genetic information is used for the benefit of individuals and society.
One of the first examples is a coordinated set of studies that examined issues surrounding genetic testing and counseling of patients for CF mutations. The investigators participating in these studies were organized into a consortium to conduct the studies more efficiently and productively, to allow a broader range of issues to be addressed, and to pursue a coordinated approach to the development of policy recommendations related to CF testing. These studies found that interest in the general population for CF testing was much lower than anticipated. The demand for CF testing was found to be influenced by a number of variables, including the cost of the test, the timing, the setting, and even the manner in which the testing was offered. It was also found that, although people can be educated about CF testing (with the goal of allowing them to make informed choices about testing), doing so is difficult because of the complexity of the information to be communicated, the lack of incentives on the part of some providers to teach people about the information, and the lack of motivation on the part of consumers to learn it. The results of this research have also led to proposals about optimal methods to provide CF testing to those who desire it. These and other results of the studies have been discussed in professional society meetings, and it is anticipated that clinical policy recommendations will emerge from these organizations.
A second major effort in the area of introduction of genetic tests was initiated in the autumn of 1994 and consists of a set of projects to examine issues surrounding testing and counseling for heritable breast, ovarian, and colon cancer risks. Questions to be addressed in these studies include the interest and demand for testing, the impact of testing, and alternative ways to provide such services. As with the CF studies, the investigators involved in these projects will form a consortium to pool resources, reduce duplication of effort, and increase coordination of some aspects of the studies. By pooling initial findings where possible and following the results of this set of research projects, it may be feasible to identify emerging themes and develop some policy recommendations sooner than if the projects were conducted and assessed independently.
In another approach to addressing issues associated with the use and regula- While much research in human genetics is focused on the causes of human disease and disability, genes and genetic markers that appear to be associated with other human characteristics are being reported on an increasingly frequent basis. Reports that associate genes with human traits that exhibit a wide range of variation in the general population, from stature, weight, and metabolism to learning ability, behavior, and sexual orientation, raise very different and potentially controversial social issues (84, 85) . Typically, such genetic studies provide only introductory and incomplete clues about the interplay of biological, psychological, and sociocultural factors that influence the development and expression of these complex human traits. However, the results of such research can be misinterpreted in two important ways. First, they can be interpreted to imply that such traits can be reduced to the expression of particular genes; this has the effect of deemphasizing the important role of psychosocial and other environmental factors. Second, the results can also be interpreted in a way that narrows the range of variation considered to be "normal" or ination on the basis of genotype. As it proceeds, the HGP will need to foster a better understanding of the meaning of human genetic variation among members of the public and the professions and expand its efforts to propose policy initiatives de- signed to prevent genetic stigmatization, discrimination, and other misinterpretation or misuses of genetic information.
Conclusion
The beginning phase of the HGP has been remarkably successful. The amount of genome data describing human DNA and the DNA of other organisms that is available in public data bases has increased enormously, and the information is being used at an increasing rate. The contributions that the HGP has already made to advance the study of inherited disease and other biological phenomena are, by now, widely recognized in the scientific community. The community is no longer arguing whether the HGP is a good idea but is now debating the most effective ways to reap its rewards.
These achievements are attributable to several decisions that were made early in the life of the program. One was to base the implementation of the program on a visionary, flexible, and on-going planning process. Over the years, the program has benefitted from advice from a large number of members of the scientific community, both from those directly involved in genome research and from those who are not but who will be the ultimate users of the products of the HGP. Second, the HGP has been highly dependent upon the introduction of new technology for mapping and sequencing, the development of which has been emphasized as part of the research program from the beginning. Further technology development will continue to be critical, not only to achieving the long-range goals of the HGP (which are, in fact, rather circumscribed), but also to the ability to take advantage of the (virtually unlimited) promise offered by the sequence-based approach to biological research that will be opened up by the HGP. Third, large research centers, both publicly and privately financed, have moved rapidly along the "learning curve" and have achieved significant efficiencies of scale that have allowed them to generate large amounts of data in relatively short periods of time. Fourth, the consensus that genomic information should be publicly available has led to policies on the part of the funding agencies and practices on the part of the genome research community that have resulted in an exemplary record for rapid publication of the data in accessible formats with the result that this valuable information is available to the scientific community much more rapidly than through conventional publication means. Finally, the international aspects of the HGP have been a demonstration of the power of an intemational collaboration in achieving a very ambitious set of goals.
We are rapidly approaching the time when we will have the initial products of the HGP, including maps, genomic DNA sequences, and the improved technology for genomic analysis, in hand. That will represent the true point of initiation for the era of sequence-based biological investigation.
Note Added in Proof. After this manuscript was submitted, several significant publications appeared addressing issues discussed in this paper. These included YAC contig maps of human chromosomes 3 (86) , 12 (87) The ideas discussed in this paper have benefitted from the long and productive collaboration that we have had with our colleagues at the NCHGR. We particularly want to thank Elke Jordan, David Benton, Carol Dahl, Bettie Graham, Jane Peterson, and Bob Strausberg for their helpful critiques and suggestions during preparation of the manuscript.
